Detalhe da pesquisa
1.
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors.
Bioorg Med Chem Lett
; 50: 128352, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34481987
2.
Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
Bioorg Med Chem
; 40: 116163, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33932711
3.
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
J Immunol
; 202(10): 2888-2906, 2019 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30988116
4.
Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
Bioorg Med Chem Lett
; 28(20): 3307-3311, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30243592
5.
Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
Bioorg Med Chem Lett
; 28(21): 3419-3424, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30290988
6.
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
Bioorg Med Chem Lett
; 28(17): 2939-2944, 2018 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30122225
7.
Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
Mol Pharmacol
; 91(3): 208-219, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28062735
8.
Corrigendum to "Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors" [Bioorgan. Med. Chem. Lett. 50 (2021) 128352].
Bioorg Med Chem Lett
; 67: 128758, 2022 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484006
9.
Btk inhibition treats TLR7/IFN driven murine lupus.
Clin Immunol
; 164: 65-77, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26821304
10.
Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity.
ChemMedChem
; 16(24): 3653-3662, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34582626
11.
Discovery of Affinity-Based Probes for Btk Occupancy Assays.
ChemMedChem
; 14(2): 217-223, 2019 01 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30521698
12.
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
J Med Chem
; 62(17): 7643-7655, 2019 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31368705
13.
Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder.
Expert Opin Pharmacother
; 13(15): 2207-13, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22957772